Inventiva S.A. (NASDAQ:IVA) Receives $12.00 Average Target Price from Brokerages

Shares of Inventiva S.A. (NASDAQ:IVA) have been assigned an average recommendation of “Moderate Buy” from the six brokerages that are presently covering the stock, MarketBeat.com reports. One research analyst has rated the stock with a hold rating and five have issued a buy rating on the company. The average twelve-month price objective among brokers that have issued ratings on the stock in the last year is $12.00.

A number of research firms recently issued reports on IVA. HC Wainwright reissued a “buy” rating and set a $13.00 price objective on shares of Inventiva in a research report on Friday, March 28th. TD Cowen assumed coverage on Inventiva in a research note on Friday, February 21st. They issued a “buy” rating and a $10.00 price target for the company. Finally, Guggenheim dropped their price objective on Inventiva from $12.00 to $9.00 and set a “buy” rating on the stock in a report on Friday.

Inventiva Price Performance

Shares of NASDAQ:IVA opened at $3.07 on Friday. The firm has a fifty day moving average of $2.77 and a two-hundred day moving average of $2.51. Inventiva has a 12-month low of $1.53 and a 12-month high of $3.98.

About Inventiva

Inventiva SA, a clinical-stage biopharmaceutical company, focuses on the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis (NASH) and other diseases. Its lead product candidate is Lanifibranor, which is in Phase III clinical trial to treat NASH. The company also develops Odiparcil for the treatment of patients with mucopolysaccharidoses type VI.